XOMA Corp. (XOMA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1163005,
    "name": "XOMA Corp.",
    "stock_name": "XOMA Corp.",
    "full_name": "XOMA Corp.",
    "name_url": "stocks-analysis/xoma-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "31.13",
    "chg": 1.37,
    "chgp": "4.6%",
    "dir": 1,
    "prev_price": "29.76",
    "mcapval": "427.30",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US98419J2069",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "75.1 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/xoma-corp-1163005-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "XOMA Corp. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/xoma-corp-changes-valuation-grade-from-risky-to-fair-amid-price-fluctuations-3707914",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/XOMACorp_valuationdot_3707914.png",
        "date": "2025-11-17 15:38:51",
        "description": "XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, currently priced at $32.64. Over the past year, it has returned 9.24%, underperforming the S&P 500. The company operates at a loss, with unfavorable valuation metrics compared to its peers in the industry."
      },
      {
        "title": "XOMA Corp. Hits New 52-Week High, Surging 70.55% This Year",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/xoma-corp-hits-new-52-week-high-surging-7055-this-year-3595593",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/XOMACorp_priceRelatedfactors_3595593.png",
        "date": "2025-10-06 17:27:54",
        "description": "XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 39.92 on October 3, 2025, reflecting a one-year gain of 70.55%. The company, with a market cap of USD 427 million, remains loss-making and does not offer dividends."
      },
      {
        "title": "XOMA Corp. Hits New 52-Week High of $39.33, Up 68.44%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/xoma-corp-hits-new-52-week-high-of-3933-up-6844-3588336",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/XOMACorp_priceRelatedfactors_3588336.png",
        "date": "2025-10-02 22:30:22",
        "description": "XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 39.33 on October 1, 2025, reflecting a 68.44% increase from its low. With a market cap of USD 427 million, the company faces challenges in profitability but remains focused on growth."
      },
      {
        "title": "XOMA Corp. Hits New 52-Week High of $38.60, Surging 65.48%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/xoma-corp-hits-new-52-week-high-of-3860-surging-6548-3586009",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/XOMACorp_priceRelatedfactors_3586009.png",
        "date": "2025-10-01 16:34:24",
        "description": "XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 38.60 on September 30, 2025, reflecting a 65.48% increase from its low. The company has a market cap of USD 427 million and faces challenges with a negative return on equity."
      },
      {
        "title": "XOMA Corp. Hits New 52-Week High of $38.48, Reflecting Strong Growth",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/xoma-corp-hits-new-52-week-high-of-3848-reflecting-strong-growth-3565249",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/XOMACorp_priceRelatedfactors_3565249.png",
        "date": "2025-09-24 13:21:19",
        "description": "XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 38.48 on September 23, 2025, reflecting a 61.44% increase from its low. With a market cap of USD 427 million, the company has a manageable debt-to-equity ratio but is currently loss-making."
      },
      {
        "title": "Is XOMA Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-xoma-corp-technically-bullish-or-bearish-3545689",
        "imagepath": "",
        "date": "2025-09-20 19:16:28",
        "description": "As of 12 August 2025, the technical trend for XOMA Corp. has changed from mildly bullish to bullish. The current technical stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend on both time frames. Daily moving averages are bullish, and the On-Balance Volume (OBV) is bullish as well. However, the KST shows a mildly bearish signal on the monthly, and Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames.\n\nIn terms of performance, XOMA Corp. has outperformed the S&P 500 with a year-to-date return of 43.04% compared to the S&P's 12.22%, and a one-year return of 31.16% versus 17.14% for the index...."
      },
      {
        "title": "Is XOMA Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-xoma-corp-overvalued-or-undervalued-3542376",
        "imagepath": "",
        "date": "2025-09-20 17:51:19",
        "description": "As of 9 March 2023, the valuation grade for XOMA Corp. has moved from attractive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, particularly given its Price to Book Value of 3.57, an EV to EBIT of -11.91, and an EV to EBITDA of -12.26, which suggest significant operational challenges. In comparison, peers such as Fusion Pharmaceuticals, Inc. report a P/E of -17.58 and Gossamer Bio, Inc. has a P/E of -4.38, highlighting that XOMA's valuation metrics are not competitive within its industry.\n\nDespite the overvaluation, XOMA Corp. has shown strong returns, with a year-to-date return of 43.04% compared to the S&P 500's 12.22%, and a three-year return of 108.83% versus the S&P 500's 70.41%. However, the negative operational ratios and the recent downgrade in valuation grade suggest caution for potential investors...."
      },
      {
        "title": "XOMA Corp. Hits New 52-Week High of $38.45, Up 61.4%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/xoma-corp-hits-new-52-week-high-of-3845-up-614-3537051",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/XOMACorp_priceRelatedfactors_3537051.png",
        "date": "2025-09-19 12:58:15",
        "description": "XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 38.45 on September 18, 2025, reflecting a 61.4% increase from its low. With a market cap of USD 427 million, the company remains unprofitable but maintains a low debt-to-equity ratio."
      },
      {
        "title": "XOMA Corp. Hits New 52-Week High of $38.34, Reflecting Strong Growth",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/xoma-corp-hits-new-52-week-high-of-3834-reflecting-strong-growth-3525823",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/XOMACorp_priceRelatedfactors_3525823.png",
        "date": "2025-09-17 15:13:27",
        "description": "XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 38.34 on September 16, 2025, reflecting a 59.25% increase from its low. The company has a market cap of USD 427 million and is currently operating at a loss, with a debt-to-equity ratio of 0.33."
      }
    ],
    "total": 14,
    "sid": "1163005",
    "stock_news_url": "https://www.marketsmojo.com/news/xoma-corp-1163005"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

XOMA Corp. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape

2025-11-17 15:38:51

XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, currently priced at $32.64. Over the past year, it has returned 9.24%, underperforming the S&P 500. The company operates at a loss, with unfavorable valuation metrics compared to its peers in the industry.

XOMA Corp. Hits New 52-Week High, Surging 70.55% This Year

2025-10-06 17:27:54

XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 39.92 on October 3, 2025, reflecting a one-year gain of 70.55%. The company, with a market cap of USD 427 million, remains loss-making and does not offer dividends.

XOMA Corp. Hits New 52-Week High of $39.33, Up 68.44%

2025-10-02 22:30:22

XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 39.33 on October 1, 2025, reflecting a 68.44% increase from its low. With a market cap of USD 427 million, the company faces challenges in profitability but remains focused on growth.

XOMA Corp. Hits New 52-Week High of $38.60, Surging 65.48%

2025-10-01 16:34:24

XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 38.60 on September 30, 2025, reflecting a 65.48% increase from its low. The company has a market cap of USD 427 million and faces challenges with a negative return on equity.

XOMA Corp. Hits New 52-Week High of $38.48, Reflecting Strong Growth

2025-09-24 13:21:19

XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 38.48 on September 23, 2025, reflecting a 61.44% increase from its low. With a market cap of USD 427 million, the company has a manageable debt-to-equity ratio but is currently loss-making.

Is XOMA Corp. technically bullish or bearish?

2025-09-20 19:16:28

As of 12 August 2025, the technical trend for XOMA Corp. has changed from mildly bullish to bullish. The current technical stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend on both time frames. Daily moving averages are bullish, and the On-Balance Volume (OBV) is bullish as well. However, the KST shows a mildly bearish signal on the monthly, and Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. In terms of performance, XOMA Corp. has outperformed the S&P 500 with a year-to-date return of 43.04% compared to the S&P's 12.22%, and a one-year return of 31.16% versus 17.14% for the index....

Is XOMA Corp. overvalued or undervalued?

2025-09-20 17:51:19

As of 9 March 2023, the valuation grade for XOMA Corp. has moved from attractive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, particularly given its Price to Book Value of 3.57, an EV to EBIT of -11.91, and an EV to EBITDA of -12.26, which suggest significant operational challenges. In comparison, peers such as Fusion Pharmaceuticals, Inc. report a P/E of -17.58 and Gossamer Bio, Inc. has a P/E of -4.38, highlighting that XOMA's valuation metrics are not competitive within its industry. Despite the overvaluation, XOMA Corp. has shown strong returns, with a year-to-date return of 43.04% compared to the S&P 500's 12.22%, and a three-year return of 108.83% versus the S&P 500's 70.41%. However, the negative operational ratios and the recent downgrade in valuation grade suggest caution for potential investors....

XOMA Corp. Hits New 52-Week High of $38.45, Up 61.4%

2025-09-19 12:58:15

XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 38.45 on September 18, 2025, reflecting a 61.4% increase from its low. With a market cap of USD 427 million, the company remains unprofitable but maintains a low debt-to-equity ratio.

XOMA Corp. Hits New 52-Week High of $38.34, Reflecting Strong Growth

2025-09-17 15:13:27

XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 38.34 on September 16, 2025, reflecting a 59.25% increase from its low. The company has a market cap of USD 427 million and is currently operating at a loss, with a debt-to-equity ratio of 0.33.

View All News